Cardiol Therapeutics Inc.
CRDL.TO
TSX
| Weiss Ratings | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.26 | |||
| Price History | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.19% | |||
| 30-Day Total Return | -30.00% | |||
| 60-Day Total Return | -33.15% | |||
| 90-Day Total Return | -45.66% | |||
| Year to Date Total Return | -39.59% | |||
| 1-Year Total Return | -53.70% | |||
| 2-Year Total Return | 72.46% | |||
| 3-Year Total Return | -41.38% | |||
| 5-Year Total Return | -53.15% | |||
| 52-Week High % Change | -69.48% | |||
| 52-Week Low % Change | 19.27% | |||
| Price | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.26 | |||
| 52-Week Low Price | $1.09 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Jun 12, 2024 | |||
| Valuation | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 75.52M | |||
| Enterprise Value | 54.13M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.38 | |||
| Earnings Per Share Growth | 16.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 6.25 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.19 | |||
| Enterprise Value/EBITDA (TTM) | -1.85 | |||
| Enterprise Value/EBIT | -1.84 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 80.41M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 289 910 0850 | |||
| Address | 2265 Upper Middle Road East Oakville, ON L6H 0G5 | |||
| Website | www.cardiolrx.com | |||
| Country | Canada | |||
| Year Founded | 2017 | |||
| Profitability | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -73.58% | |||
| Return on Equity | -- | |||
| Income Statement | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -29.28M | |||
| EBIT (TTM) | -29.40M | |||
| Net Income (TTM) | -26.80M | |||
| Net Income Avl. to Common (TTM) | -26.80M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -4.08% | |||
| EPS Diluted (TTM) | -0.38 | |||
| EPS Diluted Growth (Q YOY) | 15.56% | |||
| Balance Sheet | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 21.25M | |||
| Cash Per Share (Q) | $0.26 | |||
| Total Current Assets (Q) | 22.01M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 17.19M | |||
| Current Ratio (Q) | 4.518 | |||
| Book Value Per Share (Q) | $0.21 | |||
| Total Assets (Q) | 22.15M | |||
| Total Current Liabilities (Q) | 4.87M | |||
| Total Debt (Q) | 110.20K | |||
| Total Liabilities (Q) | 4.96M | |||
| Total Common Equity (Q) | 17.19M | |||
| Cash Flow | CRDL.TO - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -15.60K | |||
| Cash from Financing (TTM) | 13.46M | |||
| Net Change in Cash (TTM) | -3.51M | |||
| Levered Free Cash Flow (TTM) | -8.66M | |||
| Cash from Operations (TTM) | -18.32M | |||
